New Alliance Trial Aims to Improve Outcomes in Metastatic Prostate Cancer (IMAGE)
Caption
The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial—a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.
The ASPIRE trial (Alliance A032302) is enrolling 1,200 participants across the United States with metastatic castrate-sensitive prostate cancer (mCSPC). The study seeks to determine whether the addition of docetaxel, a well-established chemotherapy drug, to hormone therapy and apalutamide—a next-generation androgen receptor inhibitor that works to block testosterone growth—can improve overall survival in men newly diagnosed with mCSPC.
Credit
Alliance for Clinical Trials in Oncology
Usage Restrictions
none
License
Original content